1. Search Result
Search Result
Results for "

PKC

" in MedChemExpress (MCE) Product Catalog:

387

Inhibitors & Agonists

3

Screening Libraries

3

Fluorescent Dye

4

Biochemical Assay Reagents

58

Peptides

99

Natural
Products

5

Recombinant Proteins

19

Isotope-Labeled Compounds

22

Antibodies

1

Click Chemistry

6

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1286

    PKC Neurological Disease
    PKC β pseudosubstrate is a selective cell-permeable inhibitor of PKC .
    PKC β pseudosubstrate
  • HY-16903

    PKC Inflammation/Immunology
    PKC-IN-1 is a potent, ATP-competitive and reversible inhibitor of conventional PKC enzymes with Kis of 5.3 and 10.4 nM for human PKCβ and PKCα, and IC50s of 2.3, 8.1, 7.6, 25.6, 57.5, 314, 808 nM for PKCα, PKCβI, PKCβII, PKCθ, PKCγ, PKC mu and PKCε, respectively.
    PKC-IN-1
  • HY-W013852

    Ser/Thr Kinase Tyrosinase PKA PKC EGFR Cancer
    PKC-IN-6 (Compound 21) is a selective inhibitor of tyrosine and serine kinases. PKC-IN-6 shows inhibitory activity against PKC-α, PKC-δ, PKA, EGF-R with IC50 values of 240, >500, >500, >100 μM, respectively. PKC-IN-6 is promising for research of cancers .
    PKC-IN-6
  • HY-128142

    PKD PKC Cardiovascular Disease
    PKC/PKD-IN-1 (Compound 13C) is an orally active dual protein kinase C/D (PKC/PKD) inhibitor with an IC50 value of 0.6 nM for PKD1. PKC/PKD-IN-1 can attenuate high-salt diet-induced cardiac hypertrophy and can be used in the study of heart failure .
    PKC/PKD-IN-1
  • HY-177283

    PKC Cancer
    PKC-IN-7 is an inhibitor of PKC. PKC-IN-7 can be used in the research of diseases such as cancer .
    PKC-IN-7
  • HY-P1286A

    PKC Neurological Disease
    PKC β pseudosubstrate TFA is a selective cell-permeable inhibitor of PKC .
    PKC β pseudosubstrate TFA
  • HY-169578

    PKC Cancer
    PKC-IN-5 (Compound PKCe2054) is a PKC inhibitor. PKC-IN-5 prevents the interaction between PKCe and its adaptor protein RACK2 .
    PKC-IN-5
  • HY-P1372

    PKC Others
    PKC ζ pseudosubstrate, a PKC ζ inhibitor peptide, can be attached to cell permeabilization vector peptide .
    PKC ζ pseudosubstrate
  • HY-147712

    PKC Inflammation/Immunology
    PKC-IN-4 (compound 7l) is a potent and orally active aPKC inhibitor with an IC50 of 0.52 µM. PKC-IN-4 inhibits TNF-α induced NF-κB activity in vitro. PKC-IN-4 blocks VEGF- and TNFα-induced permeability across the retinal vasculature .
    PKC-IN-4
  • HY-P10085

    PKC Inflammation/Immunology
    PKC-ε translocation inhibitor peptide is a PKC-ε translocation inhibitor. PKC-ε translocation inhibitor peptide can regulate the rate of FcγR-mediated internalization of opsonized beads, has no effect of FcαR trafficking .
    PKC-ε translocation inhibitor peptide
  • HY-112681

    PKC Others
    PKC-theta inhibitor 2 is a potent and selective PKC-θ inhibitor with an IC50 value of 18 nM .
    PKC-theta inhibitor 2
  • HY-112681B

    PKC Others
    PKC-theta inhibitor 2 hydrochloride is a potent and selective PKC-θ inhibitor with an IC50 value of 18 nM .
    PKC-theta inhibitor 2 hydrochloride
  • HY-126146
    PKC-iota inhibitor 1
    2 Publications Verification

    PKC AMPK Metabolic Disease Cancer
    PKC-iota inhibitor 1 is a protein kinase C-iota (PKC-ι) inhibitor with an IC50 value of 0.34 μM. PKC-iota inhibitor 1 can be used for the study of cancer .
    PKC-iota inhibitor 1
  • HY-126328

    PKC Interleukin Related Inflammation/Immunology
    PKC-theta inhibitor 1 is an orally active and selective ATP-competitive inhibitor of Protein Kinase Cθ (PKCθ), with a Ki value of 6 nM. PKC-theta inhibitor 1 inhibits T-cell-mediated inflammatory responses by suppressing the release of proinflammatory cytokines (IL-2 IC50 = 0.21 μM in anti-CD3/CD28-stimulated PBMCs; IL-17 IC50 = 1 μM in CD3/CD28-stimulated Th17 cells) PKC-theta inhibitor 1 significantly reduces symptoms in mice with ongoing experimental autoimmune encephalomyelitis (EAE). PKC-theta inhibitor 1 can be used for the study of T-cell-mediated inflammatory diseases such as multiple sclerosis .
    PKC-theta inhibitor 1
  • HY-P3879

    PKC βII (660-673)

    PKC Others
    Protein Kinase C (660-673) (PKC βII (660-673)) is the PKC βII V5 peptide with RACK1-binding affinity .
    Protein Kinase C (660-673)
  • HY-P1288

    PKC fragment (530-558)

    PKC Others
    Protein Kinase C (530-558), a peptide fragment of protein kinase C (PKC), is a potent PKC activator. Protein Kinase C (530-558) significantly inhibits osteoclastic bone resorption .
    Protein Kinase C (530-558)
  • HY-P5886

    Myristoylated protein kinase C inhibitor 20-28

    PKC Cancer
    PKC 20-28,myristoylated (Myristoylated protein kinase C inhibitor 20-28) is a cell-permeable PKC inhibitor that can be used in cancer research .
    PKC 20-28,myristoylated
  • HY-10230
    Midostaurin
    30+ Cited Publications

    PKC412; CGP 41251

    PKC VEGFR c-Kit NO Synthase Apoptosis Cancer
    Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .
    Midostaurin
  • HY-10230S

    PKC412-d5; CGP 41251-d5

    Isotope-Labeled Compounds PKC Syk Akt PKA c-Kit Cancer
    Midostaurin-d5 (PKC412-d5) is a deuterium labeled Midostaurin. Midostaurin is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM .
    Midostaurin-d5
  • HY-P1746
    Protein Kinase C (19-31)
    1 Publications Verification

    PKC (19-31)

    PKC Inflammation/Immunology
    Protein Kinase C (19-31), a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31), is used as protein kinase C substrate peptide for testing the protein kinase C activity .
    Protein Kinase C (19-31)
  • HY-10230R

    PKC412 (Standard); CGP 41251 (Standard)

    Reference Standards PKC VEGFR c-Kit NO Synthase Apoptosis Cancer
    Midostaurin (Standard) is the analytical standard of Midostaurin. This product is intended for research and analytical applications. Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .
    Midostaurin (Standard)
  • HY-P1746A

    PKC (19-31) (TFA)

    PKC Inflammation/Immunology
    Protein Kinase C (19-31) TFA, a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31), is used as protein kinase C substrate peptide for testing the protein kinase C activity .
    Protein Kinase C (19-31) (TFA)
  • HY-W751179

    PKC412-13C6; CGP 41251-13C6

    Isotope-Labeled Compounds Apoptosis VEGFR PKC c-Kit NO Synthase Cancer
    Midostaurin- 13C6 (PKC412- 13C6) is the 13C-labeled Midostaurin (HY-10230). Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .
    Midostaurin-13C6
  • HY-13335

    PKC Apoptosis Cancer
    PKCβ inhibitor 1 is a potent, ATP-competitive, and selective PKCβ inhibitor with IC50s of 21 and 5 nM for human PKCβ1 and PKCβ2, respectively. PKCβ inhibitor 1 exhibits selectivity of more than 60-fold in favor of PKCβ2 relative to other PKC isozymes (PKCα, PKCγ, and PKCε) .
    PKCβ inhibitor 1
  • HY-E70856

    PKC Inflammation/Immunology
    PKCθ is a member of the Ca 2+-independent PKC subfamily. PKCθ plays an important role in T cell activation. PKCθ is also required for the survival of activated peripheral T lymphocytes. PKCθ Recombinant Human Active Protein Kinase is a recombinant PKCθ protein that can be used to study PKCθ-related functions .
    PKCθ Recombinant Human Active Protein Kinase
  • HY-E70854

    PKC Cardiovascular Disease
    PKCε is an isoform of the large PKC family of protein kinases. In cardiac muscle cells, PKCε regulates muscle contraction through its actions at sarcomeric proteins, and PKCε modulates cardiac cell metabolism through its actions at mitochondria. PKCε Recombinant Human Active Protein Kinase is a recombinant PKCε protein that can be used to study PKCε-related functions .
    PKCε Recombinant Human Active Protein Kinase
  • HY-E70852

    PKC Cancer
    PKC is a family of serine/threonine kinases involved in several processes including proliferation, differentiation, apoptosis, and migration. PKCα is a classical PKC isoform that contains a C1 domain that binds to diacylglycerol (DAG). PKCα Recombinant Human Active Protein Kinase is a recombinant PKCα protein that can be used to study PKCα-related functions .
    PKCα Recombinant Human Active Protein Kinase
  • HY-E70853

    PKC Cancer
    PKCδ is a PKC isoform. PKCδ is expressed ubiquitously among cells and tissues. It is activated by diacylglycerol produced by receptor-mediated hydrolysis of membrane inositol phospholipids as well as by tumor-promoting phorbol ester through the binding of these compounds to the C1 region in its regulatory domain. PKCδ Recombinant Human Active Protein Kinase is a recombinant PKCδ protein that can be used to study PKCδ-related functions .
    PKCδ Recombinant Human Active Protein Kinase
  • HY-120497

    PKC CDK Cancer
    PKCζ-IN-1 is a compound that inhibits PKCζ and CDK2, showing an IC50 value of 5.18 nM for PKCζ and 1.04 μM for CDK2, with significant selectivity of 200-fold. PKCζ-IN-1 can reduce the activity of CDK2 while inhibiting PKCζ.
    PKCζ-IN-1
  • HY-P3199

    PKC Inflammation/Immunology
    PKCβII Peptide Inhibitor I is a PKCβII inhibitor. PKCβII Peptide Inhibitor I shows cardioprotective effects in rat cardiac Ischemia/reperfusion injury model. PKCβII Peptide Inhibitor I also prevents vascular endothelial dysfunction .
    PKCβII Peptide Inhibitor I
  • HY-E70855

    PKC Cancer
    PKCζ is a member of the atypical PKC subfamily and has been widely implicated in the regulation of cellular functions. The major activation pathway of PKCζ depends on phosphatidylinositol (PI)-3,4,5-trisphosphate (PIP(3)), which is mainly produced by PI-3 kinase. PKCζ Recombinant Human Active Protein Kinase is a recombinant PKCζ protein that can be used to study PKCζ-related functions .
    PKCζ Recombinant Human Active Protein Kinase
  • HY-P5888

    Myr‐PKCɛ-

    PKC Inflammation/Immunology
    PKCε inhibitor peptide,myristoylated (Myr‐PKC -) is a cell permeable myristic acid conjugated PKC peptide inhibitor that attenuates NO release in cultured human umbilical vein endothelial cells (HUVECs) .
    PKCε inhibitor peptide,myristoylated
  • HY-P3816

    PKC Others
    PKCε Inhibitor Scramble Peptide is a scrambled peptide with identical amino acid composition to PKCε inhibitor peptide.
    PKCε Inhibitor Scramble Peptide
  • HY-122858

    PKC Cancer
    PKCiota-IN-2 (Compound 49) is a potent PKCiota (PKC-ι) inhibitor with an IC50 of 2.8 nM. PKCiota-IN-2 also inhibits PKC-α and PKC-ε with IC50s of 71 nM and 350 nM, respectively .
    PKCiota-IN-2
  • HY-122857

    PKC Cancer
    PKCiota-IN-1 (compound 51) is a potent PKCiota (PKC-ι) inhibitor with an IC50 of 2.7 nM. PKCiota-IN-1 also inhibits PKC-α and PKC-ε with IC50s of 45 nM and 450 nM, respectively .
    PKCiota-IN-1
  • HY-122858A

    PKC Cancer
    PKCiota-IN-2 formic is a potent PKCiota (PKC-ι) inhibitor with an IC50 of 2.8 nM. PKCiota-IN-2 formic also inhibits PKC-α and PKC-ε with IC50s of 71 nM and 350 nM, respectively .
    PKCiota-IN-2 formic
  • HY-P5885

    PKC Others
    PKCη pseudosubstrate inhibitor,myristoylated is cell permeable and can be used to study the mechanism of action of PKCη .
    PKCη pseudosubstrate inhibitor,myristoylated
  • HY-P5884

    PKC Others
    PKCθ pseudosubstrate peptide inhibitor, myristoylated is a synthetic peptide that can be used to study the mechanism of action of PKCθ .
    PKCθ pseudosubstrate peptide inhibitor,myristoylated
  • HY-P5884A

    PKC Others
    PKCθ pseudosubstrate peptide inhibitor, myristoylated TFA is a synthetic peptide that can be used to study the mechanism of action of PKCθ .
    PKCθ pseudosubstrate peptide inhibitor,myristoylated TFA
  • HY-P3201

    Pyruvate Kinase Neurological Disease
    PKCζ/ι pseudosubstrate inhibitor has broad-spectrum effects on the PKC enzyme family and can induce memory impairment .
    PKCζ/ι pseudosubstrate inhibitor
  • HY-P10421

    ERK Cancer
    PKCδ substrate acts as a nuclear transporter of ERK2 and is involved in ERK2 mediated gene activation. PKCδ is involved in the regulation of cell growth, proliferation, cell cycle arrest, and apoptosis by phosphorylating hBVR and other proteins. PKCδ substrate can be used to study the development of diseases, especially cancer biology .
    PKCδ substrate
  • HY-P3818

    PKC Others
    PKCδ Peptide Substrate is an absolutely specific substrate for the δ-type of PKC, with a sequence corresponding to sequence 422-443 of murine eEF-1α and containing Thr-431 .
    PKCδ Peptide Substrate
  • HY-P5437

    PKC Others
    PKCε (85-92) is a biological active peptide. (This peptide is the e-PKC specific activator, it also activates MARCKS phosphorylation in wild type cells, and has no effect on MARCKS phosphorylation in the cells derived from knockout mice.)
    PKCε (85-92)
  • HY-P5881

    PKC Cardiovascular Disease
    PKCα (C2-4) inhibitor peptide is a PKCα specific inhibitor peptide that blocks the inhibition of IKr by the α1A adrenoreceptor agonist A-61603 (HY-101366) .
    PKCα (C2-4) inhibitor peptide
  • HY-162234

    PKC Others
    PKCTheta-IN-1 (Compound 19) is a selective macrocyclic PKCTheta inhibitor with IC50 value of 0.1 nM .
    PKCTheta-IN-1
  • HY-164756

    PKC Inflammation/Immunology
    PKCTheta-IN-2 (compound 14) is a potent and selective PKCθ inhibitor with an IC50 of 0.25 nM. PKCTheta-IN-2 shows good selectivity over a wide range of kinases, including the PKC subfamily (30 kinases). PKCTheta-IN-2 inhibits the IL-2 production in a mouse (IC50 of 682 nM) .
    PKCTheta-IN-2
  • HY-P5452

    PKC Others
    PKCd (8-17) is a biological active peptide. (This peptide is derived from the V1 domain of protein kinase C (PKC)d. It inhibits phorbol 12-myristate 13-acetate (PMA)-induced PKCd translocation and activation. Inhibition of PKCd reduces ischemia damage in cardiac and cerebral cells, induces proliferation of fibroblasts, and inhibits graft coronary artery disease in mice.)
    PKCd (8-17)
  • HY-P1402

    PKC Others
    [Glu27]-PKC (19-36) is an inactive control for protein kinase C (PKC) (19-36). PKC (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C, it may be responsible for maintaining the enzyme in the inactive form in the absence of allosteric activators such as phospholipids .
    [Glu27]-PKC (19-36)
  • HY-144307

    Aurora Kinase PKC Cancer
    Aurora A/PKC-IN-1 (Compound 2e) is a potent dual inhibitor of Aurora A (AurA) and PKC (α, β1, β2, and θ) kinases with IC50s of 6.9 nM and 16.9 nM for AurA and PKCα, respectively. Aurora A/PKC-IN-1 has antiproliferative activity in breast cancer cells and antimetastatic activity .
    Aurora A/PKC-IN-1
  • HY-P3842

    PKC Cancer
    Protein Kinase C (661-671) is a fragment peptide of β1 subspecies of protein kinase C (PKC). PKC plays a role in cellular growth control and tumor promotion .
    Protein Kinase C (661-671)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: